Allurion Technologies Faces NYSE Delisting, Reports Significant Q1 Revenue Decline and Going Concern Doubt

summarizeSummary

Allurion Technologies has been delisted from the NYSE and faces substantial doubt about its ability to continue as a going concern, despite recent FDA approval for its key product.

check_boxKey Events

• NYSE Delisting & OTC Trading

  The company was delisted from the NYSE on March 6, 2026, due to non-compliance with the $15 million market capitalization rule and is now trading on the OTCQB Market. An additional delisting notice was received on May 11, 2026, for failing to maintain a $1.00 average closing price.

• Going Concern Doubt

  Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses, negative operating cash flows, and the potential need for additional capital.

• Significant Revenue Decline

  Revenue decreased by 47% year-over-year to $2.9 million for Q1 2026, primarily due to strategic shifts and efforts to manage credit risk with distributors.

• Increased Net Loss

  Net loss widened to $6.1 million in Q1 2026 from $1.5 million in Q1 2025.

auto_awesomeAnalysis

Allurion Technologies is in a critical financial and operational state, highlighted by its delisting from the NYSE and subsequent trading on the OTCQB market due to failing to meet listing standards. The company also disclosed substantial doubt about its ability to continue as a going concern and a breach of debt covenants. While FDA approval for its gastric balloon system offers a future opportunity, the immediate financial challenges and loss of exchange listing present significant risks to investors.